Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler profile (no major side effects in limited prior human use). A small ...
Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.
Researchers are engineering bacteria to invade tumors and consume them from the inside. Because tumor cores lack oxygen, they ...
Creatv Bio has demonstrated that monitoring the expressions of PD-L1 using the LifeTracDx ® blood test at baseline, followed by sequential sampling after induction of therapy, may identify patients ...
Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
The median age at diagnosis was 26 years, with a male predominance (96.3%). Common histological subtypes included seminoma (34.3%) and yolk sac tumor (31.3%). First-line chemotherapy comprised ...
In the article that accompanies this editorial, Nguyen Hoang et al 1 retrospectively analyzed 561 samples of 374 patients with early-stage cancer across six solid tumor types who underwent tumor ...
Crystalline polymers assembled inside tumor cell lysosomes rupture membranes, release iron, and trigger immune-activating ...
When removing cancerous tissue in the brain, neurosurgeons often use "awake brain mapping" to minimize the risk of causing unintended disruptions to a patient's quality of life while removing as much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results